We have previously reported an overexpression of Smad1 in follicular lymphoma (FL) cells, which are characterized by the t(14;18) bcl2/IgH translocation. Smad1 is commonly involved in bone morphogenetic protein but not in tumor-transforming growth factor beta (TGFb) signaling pathways. This study focuses on Smad1 signaling pathway in non-Hodgkin lymphoma cells including follicular or large-cell lymphoma cells. Our results support the notion that phosphorylation of Smad1 is mediated by TGFb present in the microenvironment and occurs in FL in vivo. Using an in vitro coculture system mimicking interactions between stroma cells and FL cells, we found that both the cell partners release TGFb at a sufficient concentration to activate Smad pathways in the malignant cells. This Smad1 activation involves TGFbRII but not ALK-1 receptors, and does not compete with the Smad2 pathway. Moreover, proliferation assays performed on lymphoma cells expressing wild-type or mutated Smad1, or in which endogenous Smad1 level was decreased by gene silencing, strongly supported that overexpression and activation of Smad1 modifies the biological response of lymphoma B cells to TGFb family members. This work opens new insights into aberrant Smad pathways and their pathophysiological role in FL and in other non-Hodgkin lymphomas.
Introduction
Smad proteins play a key role in transforming growth factor beta (TGFb) family members signal transduction. Although extensively investigated in solid tumors, Smad-associated pathways have only received limited study in hematological malignancies, specifically B-cell lymphomas. Follicular non-Hodgkin's lymphomas (FLs) are neoplastic counterparts of normal germinal center (GC) B cells. 1 In contrast to normal GC B cells, FL cells overexpress the antiapoptotic BCL-2 protein due to the t(14;18) Bcl2/IgH gene translocation. 2, 3 Using gene expression profiling, we identified Smad1 to be the most differentially overexpressed gene in FL when compared with normal GC B cells. 4 These hypoproliferative indolent lymphomas can evolve into highly proliferative diffuse large B-cell lymphomas (DLBCLs). 5, 6 Within the tumor microenvironment of FL, follicular dendritic cells (FDCs), bone marrow stromal cells (BMSCs) as well as T-lymphocytes provide cell-cell contact signals and cytokines including TNFa, which support lymphoma cell growth and survival. [7] [8] [9] [10] Through Smad1 and other Smad proteins, TGFb family members affects proliferation, survival and differentiation of normal and malignant cells, including lymphocytes. [11] [12] [13] This superfamily includes TGFb isoforms, activins (Acts) and bone morphogenetic proteins (BMPs). [14] [15] [16] The antiproliferative activity of TGFb, Acts and BMPs in lymphocytes is well established. 17, 18 However, TGFb family members modulate many other B-and T-cell responses like cell adhesion, apoptosis or cytokine secretion. [19] [20] [21] At the cell surface, TGFb, Act or BMPs bind to a type II receptor, which recruits and phosphorylates a type I receptor to form a type I/type II receptor complex. 22 The activated type I receptor provides anchorage for receptor Smad proteins (R-Smads) and subsequently induces their phosphorylation. Five R-Smads have been described: Smad1, Smad2, Smad3, Smad5 and Smad8. 23 Once phosphorylated, R-Smads associate with the common Smad4, translocate to the nucleus and regulate gene expression Smad1 and Smad5 are preferentially involved in the BMP-dependent pathways, while Smad2 and Smad3 are involved in the TGFb or Act pathways. [24] [25] [26] [27] To date, endothelial and osteosarcoma cells are the only cell types in which Smad1 is activated upon TGFb. [28] [29] [30] Endothelial cells express ALK-1 type I receptors, which associate with TGFbRII, bind TGFb and recruit Smad1. Smad2 has been shown to be activated in parallel to Smad1 in these cells. However, the two pathways target distinct genes and differentially affect the fate of the cells. 29, 31, 32 Herein, we have examined the Smad1 and Smad2 signaling pathways in FL cells and B-cell lymphoma lines stimulated by TGFb family member proteins. These studies demonstrate that Smad1, usually associated with the BMPs but not the TGFb signaling pathway, is activated following TGFb stimulation. Our observations also indicate that Smad1 plays a role in the control of cell proliferation mediated by TGFb and BMP2. Moreover, the results show that Smad1 is phosphorylated in situ in FL, and support a role of malignant B cells and normal stromal cells in this activation.
Materials and methods
Cell culture and cell stimulation Cells: GC B cells, FDC-like cells from normal tonsils, normal BMSCs and FL cells were isolated and purified as described previously, after informed consent and IRB approval. 4, 33, 34 DoHH2 (H2) and WSU-NHL were obtained from the German Collection of Micro-organisms and cell culture (DSMZ, Braunschweig). TAT-1 cells were kindly provided by Dr LD Mayer (University of British Columbia, Vancouver, BC, Canada), and DLBCL-like cell lines DHL8, DHL10 were a generous gift from Dr M Shipp (Dana-Farber Cancer Institute, Boston, MA, USA). H2, TAT-1, DHL8 and DHL10 have been described previously. 35, 36 The DHL16 cell line was established and provided by Dr Alan Epstein (University of Southern California, CA, USA). This cell line was derived from a DLBCL patient (procedure detailed in Epstein and Kaplan 37 ), and expresses the t(14;18) bcl2/IgH translocation. All B-cell lines were cultured at 371C in RPMI 1640 supplemented with 10% FCS, 2 mM pyruvate, penicillin and streptomycin (100 U/ml each) (Life Technologies, Gaithersburg, MD, USA) in a humidified 5% CO 2 atmosphere.
Mono-and coculture experiments with H2 cells: (See Supplementary data 1) for details. Briefly, H2 cells were cultured with or without FDC-LCs or BMSCs. Where indicated, TNFa (10 ng/ml) was added to the cell culture. After 2 days, cell culture supernatants (SNs) were harvested and treated with NaOH/HCl to remove TGFb from inactivating complexes. An aliquot of each SN was used to determine TGFb by ELISA (see below), and the rest of the volume was used as a source of TGFb. Serum-starved H2 cells (30 Â 10 6 ) were resuspended in 1 ml of undiluted SN prepared as described above. Controls were performed using a medium containing recombinant TGFb or TNFa, as well as SN previously incubated with or without 1 mg/ml of anti-TGFb antibody (Ab). At the indicated time, H2 cells were lysed. Smad IP and WB were performed as described below.
Antibodies, cytokines and ELISA Smad1 (#06-653), Smad1-P (#06-702) and Smad2-P (#06-829) Ab were from Upstate Biotechnologies (Lake Placid, NY, USA). Smad1 (#sc-6201), Smad2 (#sc-6200) or Smad5 (#sc-7443) Abs were from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Smad4 (ab6527) Ab from Abcam (Cambridge, MA, USA). GAPDH and anti-Flag M5 Abs were from Advanced Immunochemicals (Long Beach, CA, USA) and Sigma-Aldrich (St Louis, MO, USA), respectively. TNFa, TGFb (TGFb 1 isoform), BMP-2, BMP-7 recombinant proteins were from R&D Systems (Minneapolis, MN, USA). TGFb sandwich ELISA was performed on HCl/ NaOH-treated clarified cell culture SNs using MAB240 and BAF240 TGFb Ab pair as described by the manufacturer (R&D Systems, Minneapolis, MN, USA).
Immunoprecipitations (IP) and Western blots
Cell lysates were processed and precleared as described previously. 38 IP were performed overnight with specific Abs followed by GammaBind protein G sepharose (Pharmacia Biotech) for 30 min at 41C. Immunoprecipitated proteins or total cell lysates were boiled in reducing Laemmli buffer prior to being separated by SDS-PAGE. IP, SDS-PAGE, transfer and immunoblots (WB) were performed as described previously. 38 Smad Abs #06-653, #sc-6200, #06-702 and #06-829 were used in IP or WB are indicated in figure legends and chosen with regard to their technical capabilities (supplier data sheet). To maintain protein-protein interaction and co-IP Smad1, Smad2 and Smad4, cells were lysed in co-IP buffer (pH 7.4) containing a 100 mM NaCl, 0.5% Triton X-100, 0.1 mM EDTA, 50 mM HEPES, 1 mM DTT, 0.2 mM sodium othovanadate and protease inhibitors.
Cytoplasmic and nuclear fractions
Cytoplasmic and nuclear fractions were prepared from H2 cells using the Nuclear Extract Kit (ActiveMotif, Carlsbad, CA, USA) following the recommendations of the manufacturer, and used for Smad1 or Smad2 IP as described above. The quality of the separation was controlled by optical microscopy and by tubulin Western blotting as a marker of cytoplasmic fractions (not shown).
Viruses, cell infection and cell proliferation assays
Wild-type (wt) and mutated (mut) Smad1 constructs were kindly provided by Dr F Pouliot (Laval University, Quebec, Canada). Wt-Smad1 and mut-Smad1 contain a FLAG tag sequence in their N-termini. The Ser/Thr residues of mut-Smad1 were mutated to Ala to prevent Smad1 activation. 39 Retroviruses encoding wtSmad1 or mut-Smad1 were designed and produced at the Gene Therapy Initiative (Harvard Institute of Medicine, Boston, MA, USA) as described (see Supplementary data 2). DHL16 were infected with each virus (2 Â 10 6 particles for 10 6 cells) in 10% FCS, RPMI containing polybrene (8 mg/ml). After 6 h, cells were washed and cultured for 2 days. GFP-positive cells were sorted by flow cytometry. In parallel, DHL16 were infected with empty IRES-GFP-containing virus vectors, selected by cytometry and used as negative controls (mock or GFP-DHL16).
For proliferation assays, cells (wt-Smad1-DHL16, mut-Smad1 DHL16 or GFP-DHL16) were washed twice, resuspended in RPMI 0.1% FCS containing BMP2 or TGFb and cultured for 2 days in 96-well plates (5 Â 10 4 cells and 100 l/well). 
Tissue samples and immunohistochemistry
Immunohistochemistry for phosphospecific Ser463/465 Smad1 (Smad1-P) Ab (Ref. 9511, Cell Signaling Technology, Beverly, MA, USA) was performed on 29 formalin-fixed, paraffinembedded FL sections and six cases of reactive lymphoid tissue, including lymph nodes and tonsils. See Supplementary data 3 for details on samples and procedure. An invasive breast ductal carcinoma was used as positive control. Staining was considered positive if a distinct nuclear staining of usually low to moderate intensity was observed in more than 10% of tumor cells. Positive nuclei of endothelial cells served as internal staining control.
Results

Expression of Smad1 and other Smads in lymphoma B cells
Using WB, a very similar expression of Smad1 can be seen in all GCs but GC1 ( Figure 1a ). In contrast, FL cells expressed undetectable (FL1) to normal or high levels (FL2, FL3, FL4) of Smad1 ( Figure 1a ). This heterogeneity correlates with an overexpression of Smad1 occurring in about 64% of the FL cases (Drs U Klein and R Dalla-Favera, Columbia U., NY, personal communication, and Husson et al 4 ). We next examined lymphoma cell lines for Smad1 protein expression by WB. These lines included: FL-derived cell lines H2, TAT-1 as well as DHL16 and WSU-NHL established from DLBCLs, all positive for the bcl-2/IgH translocation, and three DLBCL lines DHL7, DHL8 and DHL10, which lack the bcl2/IgH translocation. As seen in Figure 1b , H2 and TAT-1 expressed high levels of Smad1, whereas lower amounts of the protein were found in DHL16 and WSU-NHL. Smad1 levels were low to absent in DHL7 and DHL8, but present in DHL10 (Figure 1b ). 
Phosphorylation of Smad1 and Smad2 in lymphoma B-cell lines
We investigated Smad1-dependent and -independent pathways in response to TGFb family members using H2 cells. We determined that H2 expresses both Smad1 and Smad2, and performed preliminary experiments to verify the specificity of anti-Smad1 and anti-Smad2 Abs used in IP or WB and excluded any crossreactivity with Smad2 or Smad1, respectively (Supplementary data 4). H2 cells were stimulated with TGFb, BMP2, BMP7 or Act A, and Smad1 as well as Smad2 were immunoprecipitated with specific Abs from the same cell lysates. Smad phosphorylation was revealed with phosphospecific Smad Abs. Similar to other cell types, TGFb and Act A induced phosphorylation of Smad2 in H2 cells, while BMP2 or BMP7 were without effect ( Figure 1c Expression and activation of Smad1 proteins in FL cells and lymphoma cell lines. (a) Total cell lysates from purified normal GC B cells (GC1-4) or primary FL cells (FL1-4) were analyzed by SDS-PAGE and WB using Smad1-specific Ab (#06-653). Membranes were stripped and reprobed with GAPDH Ab for protein normalization. (b) Total cell lysates from H2, DHL16, TAT-1 and WSU-NHL cell lines positive for the t(14;18), bcl2/IgH translocation, or from DHL7, DHL8 and DHL10 cell lines negative for this translocation, were analyzed by SDS-PAGE and WB using Smad1-specific Ab as in (a). Membranes were also stripped and reprobed with Smad5 Ab (#sc-7443) to demonstrate the absence of Smad1 and Smad5 crossreactivity. (c) Phosphorylation of Smad1 and Smad2 by TGFb family members in H2 cells. H2 cells were stimulated for 1 h with TGFb (10 ng/ml), BMP2 or BMP7 (200 ng/ml) or Act (100 ng/ml) and lysed in 1% NP40 lysis buffer. Cell lysates were divided into two and Smad1 (upper gel) or Smad2 (lower gel) were immunoprecipitated with anti-Smad1 (#06-653) or anti-Smad2 (sc-6200) Abs. After SDS-PAGE and WB, membranes were probed with Smad1-P (#06-702) or Smad2-P (06-829) Abs, stripped and reprobed with anti-Smad1 (#06-653) or anti-Smad2 (#06-654) Abs. (d) Smad1 is phophorylated by TGFb and BMPs in DHL10-or DHL16-expressing wt-Smad1. DHL10 cells were incubated for 1 h with indicated concentration of TGFb family members. Cell lysates were divided into two and endogenous Smad1 (upper gel) or Smad2 (lower gel) immunoprecipitated. SDS-PAGE, transfer, anti-Smad1-P or anti-Smad2-P WB, as well as anti-Smad1 or anti-Smad2 WB after stripping was performed as described in (c). (e) DHL16-expressing FLAG-tagged wt (wt-Smad1 DHL16) or mut (mut-DHL16) Smad1 was stimulated for 1 h with TGFb (10 ng/ml), BMP2 or BMP7 (200 ng/ml). Cells were lysed in 1% NP40 lysis buffer, and wt-Smad1 or mut-Smad1 was immunoprecipitated using an anti-FLAG Ab. After SDS-PAGE analysis and WB, proteins were probed with anti-Smad1-P and anti-Smad1 Ab as in c. These results are representative of three independent experiments. Note: IpC ¼ isotype-match control IP.
TGFb-mediated Smad1 activation in B-cell non-Hodgkin's lymphoma O Munoz et al in FL: Ct ¼ 22.8171.58). We also observed a dose-dependent phosphorylation of Smad1 and Smad2 when H2 cells were stimulated with increasing concentrations of TGFb (Supplementary data 5b). As a positive control to confirm the biological activity of BMP2 and BMP7, we stimulated the breast cancer line MCF-7 or endothelial cells (HUVEC) and verified that these cytokines induced the phosphorylation of Smad1 (Figure 1c) . Phosphorylation of Smad2 induced by Act A in H2 cells already confirmed its biological activity (Figure 1c, lower gel) .
We extended our phosphorylation studies to other Smad1-positive B-cell lymphoma lines TAT-1 and DHL10. As observed in H2 cells, TGFb but not BMPs induced Smad1 phosphorylation in TAT-1 (Supplementary data 5c) . In DHL10, phosphorylation of Smad1 occurred upon TGFb, BMP2 or BMP7, providing evidence that both TGFb-and BMP-mediated Smad1 pathways were present in DHL10 (Figure 1d ). To further demonstrate that Smad1 is phosphorylated upon TGFb, we expressed recombinant forms of Smad1 in DHL16, which has undetectable level of endogenous Smad1 and stimulated them with TGFb and BMPs. In DHL16 infected with a retrovirus encoding for wt Smad1 (Smad1-wt), TGFb and BMP2 induced a Smad1 phosphorylation comparable to cells expressing endogenous Smad1 (Figure 1e ). In contrast, no phosphorylation was observed in cells infected with a mutated form of Smad1 (Smad1-mut). This Smad1-mut construct cannot be phosphorylated, due to mutations of the C-terminal stretch of serine/ threonine residues into alanine. 39 In all three cell lines (H2, TAT-1 and DHL16), TGFb but not BMPs induced Smad2 phosphorylation (not shown).
Nuclear translocation of Smad1 and Smad2 and association with common Smad4
We examined the formation of Smad1/Smad4 and Smad2/Smad4 complexes in H2 cells incubated with TGFb (10 ng/ml). Over time, Smad1 or Smad2 were immunoprecipitated and association with Smad4 detected by WB. Smad1 and Smad2 were then quantified by stripping and reprobing with anti-Smad1 or Smad2 Abs. As shown in Figure 2a , a time-dependent association of Smad1 or Smad2 with Smad4 was observed upon TGFb stimulation. We next monitored the localization of Smad1 and Smad2 in H2 cells incubated with TGFb. Cytoplasmic and nuclear fractions were extracted over time, and Smad1 or Smad2 in each fraction were immunoprecipitated and analyzed by WB. In TGFb-stimulated H2 cells, Smad1-P and Smad2-P rapidly accumulated into the nucleus to reach a peak at 1 and 2 h of stimulation, respectively (Figure 2b and c) . A clear nuclear localization of the total pool of Smad2 was observed after stripping and probing the membranes for total Smad2. In contrast, the nuclear accumulation of the total pool of Smad1 was less striking. This may be due to a constant shuttling between the nucleus and the cytoplasm of nonphosphorylated Smad1 but not of Smad2. 40 However, phosphorylated Smad1 clearly remained localized in the nucleus (Figure 2b and plots 1 and 2 ). This phosphorylation decreased over time but was observed as late as 6 h of TGFb stimulation. Of note, the total pool of Smad1 (cytoplasm þ nucleus) decreased over time (Figure 2, plot 3) .
TGFbRII blocking Ab inhibits Smad1 phosphorylation and Smad1/Smad4 complexes
We tested the effect of a TGFbRII-specific Ab, which inhibits the association of TGFb to its type II receptor, on Smad1 and Smad2 phosphorylation. Preincubation of H2 cells with this Ab completely inhibited Smad1 but not Smad2 phosphorylation (Figure 3a) . The inhibitory effect of TGFbRII on Smad1 phosphorylation compared to Smad2 was further confirmed by a dose response of the Ab (Figure 3b ). This inhibition of Smad1 phosphorylation by the anti-TGFbRII Ab was also seen in similarly treated TAT-1 cells (not shown). Furthermore, the TGFbRII Ab strongly inhibited the formation of Smad1/Smad4 complexes but not the association between Smad2 and Smad4 induced by TGFb (Figure 3c) . As a control, TGFbRII Ab or irrelevant IgG had no effect when incubated alone without TGFb (Figure 3c ). These data show that TGFbRII was involved in the TGFb-induced phosphorylation of Smad1 in these B-cell lines.
Effect of Smad1 on cell proliferation
We postulated that overexpression and activation of Smad1 in B lymphoma cells affect cell proliferation in the presence of TGFb and/or BMPs. We monitored the proliferation of DHL16 cells expressing wt-DHL16, mut-DHL16 or a mock construct (GFP-DHL16). Cells were cultured for 48 h with increasing concentration of TGFb or BMP2 and [
3 H]thymidine uptake was determined ( Figure 4 ). BMP2 markedly inhibited cell proliferation in wt-DHL16 compared to mut-DHL16 or GFP-DHL16 (Figure 4) . TGFb inhibited the proliferation of wt-DHL16 and GFP-DHL16 at a very similar level, but such inhibition was strongly diminished in DHL16-expressing mut-Smad1. To further confirm an active role of Smad1 in the response of lymphoma cells to TGFb, we used the RNA interference (iRNA) technology. H2 cells were transfected with random or Smad1-specific iRNA together with a plasmid-encoding eGFP. This allowed us to track the cells positive for transfection by cytometry, thus having incorporated the iRNA. After cell sorting and overnight recovery, GFP-positive cells were incubated for 48 h with or without TGFb. TGFb was less effective at inhibiting cell proliferation in cells transfected with Smad1-specific iRNA compared to cells transfected with the random iRNA sequence (Supplementary data 6c). Smad1-specific iRNA were more efficient when suboptimal TGFb concentrations were used. The diminution of Smad1 protein expression in the presence of iRNA is shown in parallel (Supplemenatry data 6a and b). These results strongly suggest that expression and activation of Smad1 regulates at least in part the sensitivity of lymphoma cells to TGFb family members.
Coculture models and phosphorylation of Smad1 in vivo
We hypothesized that Smad1 activated in FL cells could be due to TGFb present in the malignant microenvironment containing FDCs or BMSCs. Purified FDC-LCs and BMSCs were cultured alone or with H2 cells. H2 cells as well as FDC-LCs and BMSCs were released TGFb when cultured in media alone (Figure 5a) . Moreover, coculture of H2 cells with FDC-LCs or BMSCs enhanced the TGFb secretion as compared to each cell type alone (Figure 5a ). We also tested the effect of TNFa in the production of TGFb since: TNFa modulates FDC function, and TNFa is overexpressed by FL cells. 4, 33 We found that TNFa strongly enhanced the production of TGFb by H2 cells but not FDC-LCs (Figure 5a and Supplementary data 7), suggesting that this cytokine may act on FL cells, enhance the local TGFb concentrations and thus amplify Smad activation.
TGFb-mediated Smad1 activation in B-cell non-Hodgkin's lymphoma O Munoz et al
We next examined whether TGFb-containing cell culture SNs from H2, FDC-LCs or BMSCs could activate Smad1 and Smad2 in H2 cells. As seen in Figure 5b , culture SNs from H2 cells, FDC-LCs or BMSCs induced Smad1 and Smad2 phosphorylation. A higher level of phosphorylation of Smad1 occurred using SNs from H2 cells stimulated with TNFa (10 ng/ml) or with SNs from H2 cells cocultured with FDC-LCs or BMSCs. This was consistent with the higher TGFb concentrations detected in these SNs (see Figure 5a ). TNFa alone had no effect on Smad1 phosphorylation (Figure 5b, lane 6) . Preincubation of the SNs with a TGFb neutralizing Ab prevented Smad1 or Smad2 phosphorylation, demonstrating the specificity of TGFb (Figure 5b ).
We next investigated the presence of Smad1-P in normal or FL tissues by immunohistochemistry ( Figure 6 ). Overall, 13 out of 29 (45%) samples of FL and transformed FL showed nuclear staining of usually weak to moderate intensity in more than 10% of cells. This staining involved the majority of the neoplastic cells. There was no apparent difference in the staining intensity of cells between cases of FL or transformed FL. The six cases of normal lymphoid tissue showed an absence or only rare positive cells in the GCs, but frequently contained phospho-Smad1-positive endothelial or epithelial cells. The ductal carcinoma of the breast used as positive control showed moderate to strong nuclear staining in the majority of tumor cells (Figure 6 ). This Smad1 and Smad2 associate with Smad4 and translocate to the nucleus in TGFb-stimulated H2 cells. (a): H2 cells were stimulated with TGFb (10 ng/ml). At indicated times, cells were lysed in the Co-IP buffer, and Smad1 or Smad2 were immunoprecipitated with anti-Smad1 (sc-6201) and anti-Smad2 (sc-6200) Abs, respectively. After SDS-PAGE and transfer, membranes were probed with an anti-Smad4 Ab (ab6527), stripped and reprobed with anti-Smad1 (#06-653) or anti-Smad2 (#06-654) Abs. (b and c) H2 cells were stimulated with TGFb (10 ng/ml). At indicated times, nuclear (N) and cytoplasmic (C) fractions were purified, divided into two and used to perform IP of Smad1 (b) or Smad2 (c). Proteins were separated by SDS-PAGE and Western blotted for Smad1-P (b) or Smad2-P (c). Smad1 or Smad2 was quantified after stripping as in Figure 1c . Plots 1-3: densitometry analysis: Smad1-P present in each fraction was analyzed by densitometry using the NIH Image software, and represented as a function of time (plot 1, arbitrary units, AU) or as a % of total Smad1-P (nucleus þ cytoplasm) (plot 2). The total fraction of Smad1 remaining in the cells was also calculated for each time point (plot 3): band intensities of total Smad1 (nucleus þ cytoplasm) were divided by the density at time 0 (nucleus time 0 þ cytoplasm time 0), expressed in % and plotted as a function of time. Panels a-c are representative of three different experiments. Note: IpC ¼ control IP. nNonspecific band.
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provides evidence for the presence of an active Smad1 pathway in FL but not in B cells in normal tonsils.
Discussion
In this study, using human B-cell lymphoma as a model, we have identified the activation of the Smad1 pathway under TGFb stimulation in human B cells. Moreover, our data support the presence of this pathway in vivo in FL cells, in which an overexpression of the Smad1 gene has already been reported. 4 A role of Smad1 in TGFb-mediated inhibition of cell proliferation is also suggested.
We investigated the expression and activation of Smad1 in Bcell lymphoma lines, and found that the FL-derived H2 and TAT-1 cell lines expressed the protein, as well as the DLBCL cell line DHL10 to a lesser extent. We observed that Smad1, usually considered as a BMP signal transducer, was phosphorylated in the C-terminal serine/threonine residues upon TGFb stimulation in cells expressing Smad1 endogenously or after viral infection. This strongly suggests that TGFb may activate Smad1 in all Smad1-positive B cells. In contrast, the ability of Smad1 to be Figure 3 TGFbRII blocking Ab inhibits Smad1 phosphorylation and its association with Smad4. (a) H2 cells were preincubated for 1 h with TGFbRII blocking Ab or IgG control (1 mg/ml). Cells were then stimulated with TGFb (10 ng/ml) for 30 min. Smad proteins were immunoprecipitated and Western blotted as detailed in Figure 1c. (b) H2 cells were preincubated for 1 h with increasing concentrations of TGFbRII Ab (0.1-50 mg/ml), then stimulated for 60 min with TGFb (10 ng/ml) and lysed. Phosphorylated and total Smad1 or Smad2 from each same lysate was assessed as described in Figure 1c . (c) H2 cells were preincubated with TGFbRII Ab and TGFb as in (a). After 1 h, cells were lysed in co-IP lysis buffer and Smad1 or Smad2 immunoprecipitated with anti-Smad1 (#sc-6201) and anti-Smad2 (#sc-6200). After SDS-PAGE and transfer, membranes were reprobed with Smad4 Ab, stripped and reprobed for Smad1 or Smad2 quantification. These results are representative of three different experiments. Note: IpC ¼ control IP.
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phosphorylated by BMP2 or BMP7 varied considerably from cell to cell. Our data show that once phosphorylated, Smad1 associated with Smad4 is translocated to the nucleus. Smad1/Smad4 complexes are required for DNA binding or regulation of gene transcription by Smad1. 41 Their presence further demonstrates that the phosphorylation of Smad1 observed here activates the protein, in contrast to a phosphorylation targeting its linker domain and preventing its nuclear translocation. 42 TGFb induced not only Smad1 but also Smad2 phosphorylation in H2 cells. Such an activation of Smad2 by TGFb has been widely reported in many cell types, but not in mature human B cells. The presence of both phosphorylated Smad1 and Smad2 as well as Smad1/Smad4 and Smad2/Smad4 complexes within the same cells indicates that strong expression and activation of Smad1 does not interfere with the Smad2 pathway, at least in the early events of activation. It has been reported that activation of Smad1 and Smad2 pathways in the same cell results in competition with Smad4, and that Smad4 itself is the limiting factor controlling the output signal intensity. 43 Our observation that both Smad1 and Smad2 bind to Smad4 in H2 cells indicates that Smad4 was expressed at a level sufficient to allow the formation of both complexes. Therefore, two signaling pathways could be induced by TGFb in human B-cell lymphomas: one is Smad1 dependent and has been only reported in endothelial or epithelial cells. The second, abundantly described in many cell types, involves Smad2. In this way, specific genes may be regulated in parallel. Moreover, Smad1 and Smad2 associate with different transcription factors, bind distinct DNA sequences and regulate distinct pools of genes. 41, 44 Of course, We observed that an anti-TGFbRII Ab efficiently blocked Smad1 phosphorylation as well as the formation of Smad1/ Smad4 complexes. This supports participation of TGFbRII in the TGFb-mediated Smad1 activation in B-cell non-Hodgkin's lymphoma O Munoz et al type II/type I receptor heterocomplex. The TGFbRII Ab was less effective at blocking Smad2 phosphorylation and the amount of TGFb required for inducing Smad2 phosphorylation was different than for Smad1. This suggests that two distinct TGFbbinding structures may be recruiting Smad1 or Smad2 at the membrane. ALK-1, a structure reported to play this role in endothelial cells, is unlikely to be involved. 29, 31, 32, 45 None of the cell lines examined expressed ALK-1 by RT-PCR, but expressed mRNA for other type I receptor including ALK-2, ALK-3 and ALK-5 (Supplementary data 8) . Between all these other type I receptors potentially involved in Smad1 phosphorylation, ALK-2 seems the best candidate since ALK-1 and ALK-2 specifically activate Smad1 but not Smad2, and ALK-2 but not ALK-3 has been reported to bind TGFb in vitro. 46 There is no report of Smad1 activation mediated by ALK-5. 29 Most of the FL samples tested in this study do express high Smad1 protein levels, and a TGFb-dependent activation of Smad1 is observed in FL cells purified from tissues. The high Membranes were stripped and reprobed as before for Smad1 and Smad2 quantification. IMDM incubated in the absence of cells for 2 days with or without TNFa (10 ng/ml), RPMI alone or RPMI containing recombinant TGFb (10 ng/ml) were treated like other culture SNs and used as negative or positive controls for Smad1 and Smad2 phosphorylation. All steps (cell lysis, IP, WB, stripping and reprobing) were performed as described in Figure 1c . Densitometric analysis of the bands is presented and expressed as a ratio between phosphorylated/total Smad (arbitrary units, AU). This is representative of at least three independent experiments. Note: IpC ¼ control IP. TGFb-mediated Smad1 activation in B-cell non-Hodgkin's lymphoma O Munoz et al Smad1 protein levels found in the cell lines H2 and TAT-1, but not in the majority of DLBCL cell lines or in normal GC B cells further, support the notion of overexpression of Smad1 protein in FL. This is consistent with our previous observation. 4 The recent report that Smad1 is overexpressed in EBV-negative Burkitt's lymphoma cell lines further support the relevance of Smad1 deregulation in B-cell malignancies. 47 We also detected phosphorylated forms of Smad1 by immunohistochemistry in FL cells in situ with nuclear localization. In contrast, no staining was observed in normal GC B cells. TGFb is produced by FDCs, which are intimately associated with FL cells. 8, 12, 48, 49 We observed that FDC-like cells, BMSCs and H2 cells released TGFb in the culture medium. In addition, TNFa, which is present in the FL microenvironment enhanced TGFb release by H2 cells. Moreover, Smad1 was phosphorylated in H2 cells incubated with these culture SNs and TGFb was identified using a TGFb blocking Ab. The present study does not exclude an involvement of other TGFb family members in this process, which are expressed in hematopoietic and bone marrow stroma cells. 18, 50 We found that expression of wt-Smad1 or mut-Smad1 affected the response to BMP2 and TGFb. Wt-Smad1 enhanced the inhibition mediated by BMP2, suggesting that Smad1 plays a central role in BMP2 signaling pathway. The sensitivity to BMP2 may be directly related, if not dependent on Smad1 levels in the cells. In contrast, wt-Smad1 DHL16 and mock-transfected cells responded equally to TGFb. A possible explanation is that TGFb induced other Smad1-independent pathways in the cells, which mask a potential effect of wt-Smad1. Evidence to support this is the activation of Smad2 observed in parallel with the formation of Smad1/Smad4 and Smad2/Smad4 complexes. Modulation of other factors may be required to observe an effect of wt-Smad1 overexpression on TGFb-controlled cell proliferation. This may occur in FL, in which genes including Id2 or p21 kip1 are differentially expressed and are downstream of TGFb family member signaling. 4 However, overexpression of mut-Smad1 clearly reversed the effect of TGFb, indicating that introducing an inactive Smad1 pathway interfered with the TGFb response. The finding that iRNA-mediated knockdown of Smad1 can also protect lymphoma cells from the negative effect of TGFb further emphasizes the notion that expression and activation of Smad1 modulates, at least in part, the TGFb response in lymphoma cells.
In conclusion, this study reveals a new pathway in B cells involving Smad1 and TGFb, which appears to control cell proliferation and be present in vivo in FL. Further elucidation of Smad1-targeted genes may provide new insights into the biological functions controlled by TGFb through Smad1 in neoplastic and normal B cells.
